Matches in Wikidata for { <http://www.wikidata.org/entity/Q92961644> ?p ?o ?g. }
Showing items 1 to 38 of
38
with 100 items per page.
- Q92961644 description "artículu científicu espublizáu n'abril de 2019" @default.
- Q92961644 description "scientific article published on 08 April 2019" @default.
- Q92961644 description "wetenschappelijk artikel" @default.
- Q92961644 description "наукова стаття, опублікована 8 квітня 2019" @default.
- Q92961644 description "գիտական հոդված հրատարակված 2019 թվականի ապրիլի 8-ին" @default.
- Q92961644 name "miR-103a-2-5p/miR-30c-1-3p inhibits the progression of prostate cancer resistance to androgen ablation therapy via targeting androgen receptor variant 7" @default.
- Q92961644 name "miR-103a-2-5p/miR-30c-1-3p inhibits the progression of prostate cancer resistance to androgen ablation therapy via targeting androgen receptor variant 7" @default.
- Q92961644 type Item @default.
- Q92961644 label "miR-103a-2-5p/miR-30c-1-3p inhibits the progression of prostate cancer resistance to androgen ablation therapy via targeting androgen receptor variant 7" @default.
- Q92961644 label "miR-103a-2-5p/miR-30c-1-3p inhibits the progression of prostate cancer resistance to androgen ablation therapy via targeting androgen receptor variant 7" @default.
- Q92961644 prefLabel "miR-103a-2-5p/miR-30c-1-3p inhibits the progression of prostate cancer resistance to androgen ablation therapy via targeting androgen receptor variant 7" @default.
- Q92961644 prefLabel "miR-103a-2-5p/miR-30c-1-3p inhibits the progression of prostate cancer resistance to androgen ablation therapy via targeting androgen receptor variant 7" @default.
- Q92961644 P1433 Q92961644-7BA261D7-A5C0-4041-A723-439AAF323C36 @default.
- Q92961644 P1476 Q92961644-EB0ED2BD-6639-40D1-BA37-A2272BA92035 @default.
- Q92961644 P2093 Q92961644-B07FFAC3-F033-451D-8CB7-5221C9DA524A @default.
- Q92961644 P2093 Q92961644-EEEF8A49-7BE5-4E12-A579-E9271B415B22 @default.
- Q92961644 P304 Q92961644-D636A4A1-860A-477F-8783-30AEB4BC29A4 @default.
- Q92961644 P31 Q92961644-12EC3BE1-46E7-4B14-92C2-D13BA98D6899 @default.
- Q92961644 P356 Q92961644-C679F242-98AD-4CA1-963B-E8BB02E30C2B @default.
- Q92961644 P433 Q92961644-82AF5763-6209-410F-A10D-CDE2FFF13907 @default.
- Q92961644 P478 Q92961644-8CDAECBD-071A-4390-A5B4-17C93219B75B @default.
- Q92961644 P50 Q92961644-A46D2284-C281-4B72-832B-D118758AF279 @default.
- Q92961644 P577 Q92961644-01A77736-542E-400D-A326-B2EE289F1AA4 @default.
- Q92961644 P698 Q92961644-5428958D-0ED3-49EC-9653-4B1842413E52 @default.
- Q92961644 P356 JCB.28680 @default.
- Q92961644 P698 30963631 @default.
- Q92961644 P1433 Q6294917 @default.
- Q92961644 P1476 "miR-103a-2-5p/miR-30c-1-3p inhibits the progression of prostate cancer resistance to androgen ablation therapy via targeting androgen receptor variant 7" @default.
- Q92961644 P2093 "Keqin Zhou" @default.
- Q92961644 P2093 "Wenjie Chen" @default.
- Q92961644 P304 "14055-14064" @default.
- Q92961644 P31 Q13442814 @default.
- Q92961644 P356 "10.1002/JCB.28680" @default.
- Q92961644 P433 "8" @default.
- Q92961644 P478 "120" @default.
- Q92961644 P50 Q92961637 @default.
- Q92961644 P577 "2019-04-08T00:00:00Z" @default.
- Q92961644 P698 "30963631" @default.